How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

204 results for

Clinical Index of Stable Febrile Neutropenia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

201. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer

of the analysis was that of the Spanish health care payer. Direct costs considered in the analysis included: hospitalisations (number of days due to drug administration, adverse events, diagnostic procedures, febrile neutropenia, and other reasons), transfusions, health care professional visits, (oncologist, general physician, emergency room, other visits), chemotherapy administration, concomitant medications, and radiotherapy. Since treatment did not extend beyond one year, discounting was not necessary (...) , Rosell R, Cardenal F, Anton A, Lomas M, Alberola V, Massuti B, Carrato A, Minshall M. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer. Lung Cancer 2000; 28(2): 97-107 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /economics; Cisplatin /administration & Clinical

2000 NHS Economic Evaluation Database.

202. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer

determined the sample size. Study design Randomised clinical trial based at 45 different sites in eight countries in Europe. All patients were treated until disease progression, unacceptable toxicity, stable disease for 18 weeks, or patient refusal. Analysis of effectiveness The analysis of the clinical study was based on intention to treat. The primary health outcome used was mean survival time for each of the treatment arms. Effectiveness results Vinorelbine alone resulted in a mean survival time (...) + cisplatin versus vindesine + cisplatin was $1,570; the incremental cost per patient of vindesine + cisplatin versus vinorelbine alone was $1,150; and the incremental cost per patient of vinorelbine + cisplatin versus vinorelbine alone was $2,700. The only toxicity that would incur significant cost, febrile neutropenia requiring hospitalization, occurred only 20 times during more than 9,000 weeks of chemotherapy experience and did not vary significantly among the three treatment arms. The cost of the two

1995 NHS Economic Evaluation Database.

203. Clinical practice guidelines for the management of advanced breast cancer

Clinical practice guidelines for the management of advanced breast cancer i Clinical practice guidelines for the management of advanced breast cancer Clinical practice guidelines for the management of advanced breast cancer Prepared by the iSource National Breast Cancer Centre Advanced Breast Cancer Working Group Endorsed January 2001ii Clinical practice guidelines for the management of advanced breast cancer © Commonwealth of Australia 2001 ISBN Print: 0642455457 Online: 0642455465 This work (...) Clinical practice guidelines for the management of advanced breast cancer has been endorsed without inclusion of a comparative economic analysis of the costs associated with their implementation. It is the understanding of the NHMRC that an up-to-date economic analysis will be included when the Clinical practice guidelines of the management of advanced breast cancer are next updated. This document is sold through AusInfo Government Info Bookshops at a price which covers the cost of printing

2000 Cancer Australia

204. Clinical practice guidelines for the management of early breast cancer

to I 298 6.2 cyclophosphamide, methotrexate and 5-fluoro- uracil (CMF) for both recurrence-free survival and overall survival at the increased risk of alopecia, cardiac toxicity and febrile neutropenia. 16.Dose intensity is important to outcome in II 311 6.2 adjuvant cytotoxic therapy, at least in dose ranges achievable without colony stimulating factor (CSF) support. 17.T reatment with high-dose chemotherapy outside II 314, 315 6.2 of clinical trials is not recommended. 18.Women should be fully (...) : AIHW (Cancer Series).12 Clinical practice guidelines for the management of early breast cancer Mortality Age-standardised rates have remained stable, at around 25–27 deaths per 100,000 woman-years between 1982 and 1996. 20 Survival The report Breast cancer survival in Australian women 1982–1994 showed that five-year relative survival in Australian women of all ages increased from 74.4 per cent in 1982–1987 to 78.9 per cent in 1988–1992. 21 Survival was best in women aged in their 40s and poorer

2001 Cancer Australia

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>